Opsona Therapeutics Ltd, an Irish medical discovery company that targets the innate immune system as a way of treating autoimmune and inflammatory diseases, has raised €18 million in a Series B financing provided by the Novartis Venture Fund, Fountain Healthcare Partners, Inventages Venture Capital and Seroba Kernel Life Sciences.
